Various industry representatives have voiced their objections at the U.S. Patent and Trademark Office about a proposal introduced by the Biden administration last year. The contentious proposal aims to potentially exercise “march-in” rights and appropriate pharmaceutical patents using the mechanisms of the Bayh-Dole Act.
This proposal, which has incited much debate across industry groups, may allow the government to effectively “march-in” and seize patents on drugs developed with federal funding. The right to do so is granted by the Bayh-Dole Act, legislation dating back to 1980 that covers inventions stemming from federal research funding.
While the specifics of the objections and the details of the proposal are not elaborated upon, it’s clear that this proposition has drawn the attention of multiple industry groups. The renewed dispute indicates that intellectual property rights, particularly within the pharmaceutical sector, continue to be a field of intense contention and scrutiny.
For further reading, be sure to check the original article on Law360.